Does the media refer more to RARE or ELAN?

In the previous week, Ultragenyx Pharmaceutical had 4 more articles in the media than Elanco Animal Health. MarketBeat recorded 7 mentions for Ultragenyx Pharmaceutical and 3 mentions for Elanco Animal Health. Ultragenyx Pharmaceutical's average media sentiment score of 1.20 beat Elanco Animal Health's score of 0.78 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elanco Animal Health 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RARE or AXSM?

In the previous week, Axsome Therapeutics had 8 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 15 mentions for Axsome Therapeutics and 7 mentions for Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical's average media sentiment score of 1.20 beat Axsome Therapeutics' score of 0.76 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RARE or SMMT?

In the previous week, Ultragenyx Pharmaceutical had 4 more articles in the media than Summit Therapeutics. MarketBeat recorded 7 mentions for Ultragenyx Pharmaceutical and 3 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 1.67 beat Ultragenyx Pharmaceutical's score of 1.20 indicating that Summit Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to RARE or ABVX?

In the previous week, Ultragenyx Pharmaceutical had 1 more articles in the media than Abivax. MarketBeat recorded 7 mentions for Ultragenyx Pharmaceutical and 6 mentions for Abivax. Ultragenyx Pharmaceutical's average media sentiment score of 1.20 beat Abivax's score of 0.81 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Abivax 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate RDY or RARE?

Ultragenyx Pharmaceutical has a consensus price target of $58.41, indicating a potential upside of 82.37%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher possible upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Ultragenyx Pharmaceutical 1 Sell rating(s) 2 Hold rating(s) 14 Buy rating(s) 1 Strong Buy rating(s) 2.83

Ultragenyx Pharmaceutical (RARE) Competitors

$32.03 -1.19 (-3.58%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$32.24 +0.20 (+0.64%)

As of 04:14 AM Eastern

Compare

RARE vs. ELAN, AXSM, SMMT, ABVX, and RDY

Should you buy Ultragenyx Pharmaceutical stock or one of its competitors? MarketBeat compares Ultragenyx Pharmaceutical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ultragenyx Pharmaceutical include Elanco Animal Health (ELAN), Axsome Therapeutics (AXSM), Summit Therapeutics (SMMT), Abivax (ABVX), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry.

How does Ultragenyx Pharmaceutical compare to Elanco Animal Health?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

Elanco Animal Health has a net margin of -4.95% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. Elanco Animal Health's return on equity of 7.42% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%
Elanco Animal Health	-4.95%	7.42%	3.66%

Ultragenyx Pharmaceutical has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.68, suggesting that its share price is 68% more volatile than the broader market.

In the previous week, Ultragenyx Pharmaceutical had 4 more articles in the media than Elanco Animal Health. MarketBeat recorded 7 mentions for Ultragenyx Pharmaceutical and 3 mentions for Elanco Animal Health. Ultragenyx Pharmaceutical's average media sentiment score of 1.20 beat Elanco Animal Health's score of 0.78 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elanco Animal Health	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ultragenyx Pharmaceutical presently has a consensus target price of $58.41, suggesting a potential upside of 82.37%. Elanco Animal Health has a consensus target price of $28.55, suggesting a potential upside of 11.68%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher possible upside, equities analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Elanco Animal Health has higher revenue and earnings than Ultragenyx Pharmaceutical. Elanco Animal Health is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$673M	4.69	-$575M	-$6.11	N/A
Elanco Animal Health	$4.72B	2.71	-$232M	-$0.50	N/A

97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are owned by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are owned by insiders. Comparatively, 1.1% of Elanco Animal Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Ultragenyx Pharmaceutical beats Elanco Animal Health on 9 of the 16 factors compared between the two stocks.

How does Ultragenyx Pharmaceutical compare to Axsome Therapeutics?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

Ultragenyx Pharmaceutical has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market.

Axsome Therapeutics has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$673M	4.69	-$575M	-$6.11	N/A
Axsome Therapeutics	$638.50M	18.96	-$183.17M	-$3.73	N/A

Ultragenyx Pharmaceutical currently has a consensus price target of $58.41, suggesting a potential upside of 82.37%. Axsome Therapeutics has a consensus price target of $259.05, suggesting a potential upside of 10.11%. Given Ultragenyx Pharmaceutical's higher probable upside, equities research analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.95

Axsome Therapeutics has a net margin of -26.59% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. Axsome Therapeutics' return on equity of -267.16% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

In the previous week, Axsome Therapeutics had 8 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 15 mentions for Axsome Therapeutics and 7 mentions for Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical's average media sentiment score of 1.20 beat Axsome Therapeutics' score of 0.76 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are owned by insiders. Comparatively, 20.6% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Axsome Therapeutics beats Ultragenyx Pharmaceutical on 11 of the 16 factors compared between the two stocks.

How does Ultragenyx Pharmaceutical compare to Summit Therapeutics?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.

Ultragenyx Pharmaceutical has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.26, meaning that its share price is 226% less volatile than the broader market.

Ultragenyx Pharmaceutical presently has a consensus target price of $58.41, suggesting a potential upside of 82.37%. Summit Therapeutics has a consensus target price of $26.97, suggesting a potential upside of 74.36%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, equities research analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Summit Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.44

Ultragenyx Pharmaceutical has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$673M	4.69	-$575M	-$6.11	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A

97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are held by insiders. Comparatively, 83.5% of Summit Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summit Therapeutics has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. Summit Therapeutics' return on equity of -291.24% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%
Summit Therapeutics	N/A	-291.24%	-243.07%

In the previous week, Ultragenyx Pharmaceutical had 4 more articles in the media than Summit Therapeutics. MarketBeat recorded 7 mentions for Ultragenyx Pharmaceutical and 3 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 1.67 beat Ultragenyx Pharmaceutical's score of 1.20 indicating that Summit Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Ultragenyx Pharmaceutical beats Summit Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Ultragenyx Pharmaceutical compare to Abivax?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Abivax (NASDAQ:ABVX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Abivax has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Abivax is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$673M	4.69	-$575M	-$6.11	N/A
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

Ultragenyx Pharmaceutical has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market. Comparatively, Abivax has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market.

97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. Comparatively, 47.9% of Abivax shares are owned by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Abivax has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. Abivax's return on equity of -99.02% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%
Abivax	N/A	-99.02%	-70.26%

Ultragenyx Pharmaceutical currently has a consensus price target of $58.41, suggesting a potential upside of 82.37%. Abivax has a consensus price target of $148.54, suggesting a potential upside of 10.10%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher possible upside, research analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
Abivax	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

In the previous week, Ultragenyx Pharmaceutical had 1 more articles in the media than Abivax. MarketBeat recorded 7 mentions for Ultragenyx Pharmaceutical and 6 mentions for Abivax. Ultragenyx Pharmaceutical's average media sentiment score of 1.20 beat Abivax's score of 0.81 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Abivax	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ultragenyx Pharmaceutical beats Abivax on 10 of the 15 factors compared between the two stocks.

How does Ultragenyx Pharmaceutical compare to Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories (NYSE:RDY) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Ultragenyx Pharmaceutical has a consensus price target of $58.41, indicating a potential upside of 82.37%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher possible upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. Dr. Reddy's Laboratories' return on equity of 12.34% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	12.90%	12.34%	8.24%
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%

Dr. Reddy's Laboratories has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market.

In the previous week, Dr. Reddy's Laboratories had 1 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 8 mentions for Dr. Reddy's Laboratories and 7 mentions for Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical's average media sentiment score of 1.20 beat Dr. Reddy's Laboratories' score of 0.11 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dr. Reddy's Laboratories	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Ultragenyx Pharmaceutical	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dr. Reddy's Laboratories has higher revenue and earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$3.58B	3.00	$456M	$0.58	22.15
Ultragenyx Pharmaceutical	$673M	4.69	-$575M	-$6.11	N/A

Summary

Ultragenyx Pharmaceutical beats Dr. Reddy's Laboratories on 9 of the 17 factors compared between the two stocks.

Get Ultragenyx Pharmaceutical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RARE vs. The Competition

Export

Metric	Ultragenyx Pharmaceutical	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.27B	$3.68B	$6.86B	$12.44B
Dividend Yield	N/A	2.19%	2.68%	8.42%
P/E Ratio	-5.24	20.98	26.96	24.38
Price / Sales	4.69	311.10	518.38	91.92
Price / Cash	N/A	143.66	48.59	59.36
Price / Book	-38.59	8.54	10.90	6.33
Net Income	-$575M	$23.83M	$3.59B	$331.02M
7 Day Performance	-7.61%	-2.77%	-1.51%	-0.33%
1 Month Performance	26.20%	5.85%	2.76%	-1.29%
1 Year Performance	17.76%	52.15%	28.54%	21.30%

Ultragenyx Pharmaceutical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RARE Ultragenyx Pharmaceutical	3.6293 of 5 stars	$32.03 -3.6%	$58.41 +82.4%	+9.6%	$3.27B	$673M	N/A	1,371	Positive News
ELAN Elanco Animal Health	3.5419 of 5 stars	$25.13 +1.2%	$28.55 +13.6%	+71.8%	$12.40B	$4.72B	N/A	9,400
AXSM Axsome Therapeutics	3.2695 of 5 stars	$228.28 -2.4%	$259.05 +13.5%	+109.4%	$12.03B	$638.50M	N/A	380
SMMT Summit Therapeutics	3.6757 of 5 stars	$15.30 +0.3%	$26.97 +76.3%	-39.1%	$11.84B	N/A	N/A	110	Positive News
ABVX Abivax	2.1407 of 5 stars	$135.98 -2.8%	$148.54 +9.2%	+1,427.9%	$11.16B	N/A	N/A	61

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RARE) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ultragenyx Pharmaceutical (RARE) Competitors

RARE vs. ELAN, AXSM, SMMT, ABVX, and RDY

How does Ultragenyx Pharmaceutical compare to Elanco Animal Health?

Summary

How does Ultragenyx Pharmaceutical compare to Axsome Therapeutics?

Summary

How does Ultragenyx Pharmaceutical compare to Summit Therapeutics?

Summary

How does Ultragenyx Pharmaceutical compare to Abivax?

Summary

How does Ultragenyx Pharmaceutical compare to Dr. Reddy's Laboratories?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RARE vs. The Competition

Ultragenyx Pharmaceutical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ultragenyx Pharmaceutical (RARE) Competitors

RARE vs. ELAN, AXSM, SMMT, ABVX, and RDY

How does Ultragenyx Pharmaceutical compare to Elanco Animal Health?

Is RARE or ELAN more profitable?

Which has more volatility and risk, RARE or ELAN?

Does the media refer more to RARE or ELAN?

Do analysts recommend RARE or ELAN?

Which has preferable valuation and earnings, RARE or ELAN?

Do institutionals and insiders hold more shares of RARE or ELAN?

Summary

How does Ultragenyx Pharmaceutical compare to Axsome Therapeutics?

Which has more risk & volatility, RARE or AXSM?

Which has stronger earnings & valuation, RARE or AXSM?

Do analysts recommend RARE or AXSM?

Is RARE or AXSM more profitable?

Does the media refer more to RARE or AXSM?

Do institutionals & insiders hold more shares of RARE or AXSM?

Summary

How does Ultragenyx Pharmaceutical compare to Summit Therapeutics?

Which has more risk & volatility, RARE or SMMT?

Do analysts rate RARE or SMMT?

Which has better valuation and earnings, RARE or SMMT?

Do institutionals and insiders hold more shares of RARE or SMMT?

Is RARE or SMMT more profitable?

Does the media refer more to RARE or SMMT?

Summary

How does Ultragenyx Pharmaceutical compare to Abivax?

Which has higher earnings & valuation, RARE or ABVX?

Which has more volatility & risk, RARE or ABVX?

Do insiders and institutionals hold more shares of RARE or ABVX?

Is RARE or ABVX more profitable?

Do analysts rate RARE or ABVX?

Does the media refer more to RARE or ABVX?

Summary

How does Ultragenyx Pharmaceutical compare to Dr. Reddy's Laboratories?

Do insiders & institutionals have more ownership in RDY or RARE?

Do analysts rate RDY or RARE?

Is RDY or RARE more profitable?

Which has more volatility and risk, RDY or RARE?

Does the media favor RDY or RARE?

Which has better earnings & valuation, RDY or RARE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RARE vs. The Competition

Ultragenyx Pharmaceutical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools